Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-215 vs D215 in advanced BRCA-mutated ovarian cancer
NCT07532148Phase 1Not yet recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of CKD-215 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve over the dosing interval and Maximum steady-state plasma concentration. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CKD-215
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07532148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532148.